Claire Mazumdar, chief executive officer of Bicara Therapeutics Inc. (NASDAQ:BCAX), completed a set of related equity transactions in mid-March 2026 that included an option exercise followed by a sale of the resulting shares.
Between March 18 and March 20, 2026, Mazumdar sold a total of 14,900 shares of Bicara common stock for aggregate proceeds of approximately $282,365. The disposition took place at per-share prices in the range of $18.7842 to $18.9513.
On the same dates, Mazumdar exercised options to acquire the identical amount of Bicara common stock - 14,900 shares - at an exercise price of $3.7898 per share, representing a total cash outlay of $56,847 for the option exercise.
The sales followed a period in which Bicara shares rallied sharply: the stock delivered an 80% return over the prior six months, according to InvestingPro data. InvestingPro also notes that at a current market price of $18.43 the stock is considered slightly overvalued relative to its Fair Value.
Separately, Bicara recently completed an underwritten public offering that generated roughly $172.5 million in gross proceeds. The transaction consisted of 8,581,250 shares of common stock and pre-funded warrants. The common stock portion of the offering was priced at $16.00 per share. Pre-funded warrants were sold at $15.9999 per unit with an exercise price of $0.0001 per share.
The offering made use of the underwriters' option, with 1,406,250 additional shares sold under that option and the option fully exercised. The completed deal follows an earlier announcement of a planned $150 million stock offering at the same price per share, a sequence that the company and investors interpreted as evidence of robust demand.
In coverage of the company, Citizens reiterated a Market Outperform rating for Bicara and maintained a $31.00 price target. That valuation reflects the firm’s discounted earnings per share and revenue multiple analysis. Bicara also disclosed that it presented long-term follow-up data at the 2026 MHNCS conference, an update the research firm cited as potentially supporting its positive view.
The transactions and financing activity occurred in a compressed timeframe and align with both insider option exercises and significant capital raises. Public valuation metrics cited by InvestingPro and the analyst affirmation from Citizens provide contrasting context to the insider sale and the company’s recent fundraising.